Literature DB >> 8910616

Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma.

R S Warren1, H Yuan, M R Matli, N Ferrara, D B Donner.   

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenic hormone that is produced by and supports the growth of many types of malignancies. The present study shows that insulin-like growth factor 1 (IGF-I), a mitogen that promotes the propagation of cancers through autocrine and paracrine mechanisms, increases the expression of mRNA for VEGF and production of VEGF protein by COLO 205 colon carcinoma cells. IGF-I also induces expression of VEGF mRNA in SW620, LSLiM6, and HCT15 colon carcinoma cells showing that this is a common response to IGF-I. Whereas IGF-I induced VEGF mRNA in each cell line examined (2.3-12-fold), it induced proliferation only in COLO 205 and LSLiM6 cells. Thus, the proliferative response induced by IGF-I and its ability to induce VEGF occur through distinguishable mechanisms. IGF-I increases the cellular content of VEGF mRNA by increasing the rate of transcription (5-fold after 4 h) and also by increasing the half-life of VEGF mRNA (0.6 +/- 0.07 h in control cells to 2.0 +/- 0.37 h in IGF-I-treated cells). Monoclonal antibody (alphaIR3) directed against the type 1 IGF receptor significantly attenuated the ability of IGF-I to promote expression of VEGF mRNA. Interestingly, by itself alphaIR3 acted as a weak agonist and induced a modest increase in the cellular content of VEGF mRNA. alphaIR3 also promoted tyrosine phosphorylation of the beta subunit of the IGF-I receptor, and the magnitude of this response was comparable with that induced by IGF-I. These observations point to a nonlinear relationship between activation of the IGF-I receptor and induction of VEGF mRNA. Thus, in addition to its direct, growth stimulatory effect on transformed cells, IGF-I induces the expression of VEGF which can promote the progression of cancer by regulating the development of new blood vessels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8910616     DOI: 10.1074/jbc.271.46.29483

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 2.  The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.

Authors:  M Davies; S Gupta; G Goldspink; M Winslet
Journal:  Int J Colorectal Dis       Date:  2005-06-16       Impact factor: 2.571

Review 3.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

4.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

5.  Possible involvement of IGF-1 receptor and IGF-binding protein in insulin-induced enhancement of noradrenaline response in diabetic rat aorta.

Authors:  Tsuneo Kobayashi; Akihito Kaneda; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 6.  The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis.

Authors:  Raxitkumar Jinjuvadia; Prateek Lohia; Chetna Jinjuvadia; Sergio Montoya; Suthat Liangpunsakul
Journal:  J Clin Gastroenterol       Date:  2013-01       Impact factor: 3.062

7.  Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT.

Authors:  E Zelzer; Y Levy; C Kahana; B Z Shilo; M Rubinstein; B Cohen
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

Review 8.  Diabetes and cancer: Associations, mechanisms, and implications for medical practice.

Authors:  Chun-Xiao Xu; Hong-Hong Zhu; Yi-Min Zhu
Journal:  World J Diabetes       Date:  2014-06-15

Review 9.  Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis.

Authors:  Jae Moon Yoon; Ki Young Son; Chun Sick Eom; Daniel Durrance; Sang Min Park
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

10.  IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer.

Authors:  Gerrit Peters; Silvia Gongoll; Cord Langner; Michael Mengel; Pompiliu Piso; Jürgen Klempnauer; Josef Rüschoff; Hans Kreipe; Reinhard von Wasielewski
Journal:  Virchows Arch       Date:  2003-07-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.